US Broker Ratings

Delcath Systems, Inc. (DCTH) Stock Analysis: Exploring a Potential 125% Upside in the Medical Devices Sector

For investors with an appetite for healthcare innovations, Delcath Systems, Inc. (NASDAQ: DCTH) presents a compelling opportunity within the medical devices industry. This New York-based company specializes in interventional oncology,..

Mind Medicine (MindMed) Inc. (MNMD) Stock Analysis: Exploring a Promising 90% Upside Potential

For investors keen on the biotech sector, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) presents a fascinating opportunity with its significant upside potential. As a clinical-stage biopharmaceutical company, MindMed is dedicated..

Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Biotech Pioneer with 61% Potential Upside

Enliven Therapeutics, Inc. (NASDAQ: ELVN) is making waves in the biotechnology sector, attracting investor attention with a compelling potential upside of 61.18%. As a clinical-stage biopharmaceutical company, Enliven is dedicated..

Nuvation Bio Inc. (NUVB) Stock Analysis: Unveiling a 122.64% Upside in the Biotech Sector

For investors with a keen eye on the biotech sector, Nuvation Bio Inc. (NASDAQ: NUVB) presents a compelling opportunity with a staggering potential upside of 122.64%, according to analyst target..

Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a 53.75% Upside in the Biotech Sector

For investors keen on the biotechnology sector, Upstream Bio, Inc. (UPB) has garnered significant attention. With a market capitalization of $1.67 billion, UPB operates within the healthcare sector, focusing specifically..

uniQure N.V. (QURE) Stock Analysis: A Biotech Player with 127.68% Potential Upside

For investors with a keen eye on the biotechnology sector, uniQure N.V. (NASDAQ: QURE) presents a compelling case. Based in Amsterdam, the Netherlands, uniQure focuses on developing treatments for rare..

Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Unpacking a 70% Upside Potential

Nurix Therapeutics, Inc. (NRIX), a clinical-stage biopharmaceutical company, has captured investor attention with its innovative approach to drug discovery and development. Focusing on small molecule and antibody therapies, the company..

REGENXBIO Inc. (RGNX) Stock Analysis: Eyeing a 167% Potential Upside Amidst Biotech Innovations

Investors with an interest in the biotechnology sector may want to pay close attention to REGENXBIO Inc. (NASDAQ: RGNX), a clinical-stage biotech company making strides in gene therapy development. With..

Arcus Biosciences, Inc. (RCUS): Analyst Consensus Signals 51% Upside Potential Amid Robust Clinical Pipeline

Investors focusing on the biotechnology sector have been keeping a close watch on Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical firm that is making strides in the development of innovative..

AxoGen, Inc. (AXGN) Stock Analysis: Exploring a 23.5% Revenue Growth and 8.82% Upside Potential

AxoGen, Inc. (NASDAQ: AXGN), a prominent player in the healthcare sector, particularly within the medical devices industry, has been making waves with its innovative technologies for peripheral nerve regeneration and..

CeriBell, Inc. (CBLL) Stock Analysis: Navigating Growth with a 37.75% Potential Upside

CeriBell, Inc. (NASDAQ: CBLL), a prominent player in the medical devices industry, currently operates at the intersection of healthcare technology and neurological innovation. With a market capitalization of $757.86 million,..

Kura Oncology, Inc. (KURA) Growth Potential: Analyst Ratings Suggest a 295.93% Upside

For investors seeking opportunities in the dynamic biotechnology sector, Kura Oncology, Inc. (NASDAQ: KURA) presents a compelling case with significant growth potential. Headquartered in San Diego, California, Kura Oncology is..

Spyre Therapeutics, Inc. (SYRE) Stock Analysis: Biotechnology Innovator with 68% Upside Potential

Spyre Therapeutics, Inc. (SYRE) is capturing the attention of investors with a striking 68.04% potential upside, according to recent analyst ratings. This compelling figure places the biotechnology company, which specializes..

Intellia Therapeutics, Inc. (NTLA) Stock Analysis: Potential 71.63% Upside with Groundbreaking Gene Editing Innovations

Intellia Therapeutics, Inc. (NASDAQ: NTLA) has captured the attention of investors in the biotechnology sector with its pioneering work in gene editing. As a clinical-stage company, Intellia is at the..

Beta Bionics, Inc. (BBNX) Stock Analysis: A Promising 105.91% Upside in the Medical Device Sector

Beta Bionics, Inc. (NASDAQ: BBNX) stands out as a compelling player in the healthcare sector, specifically within the medical devices industry. With a market capitalization of $651.12 million, the company..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Strong Revenue Growth and Attractive Valuation with 17.24% Upside Potential

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) stands out in the healthcare sector with its focus on developing and commercializing innovative pain management solutions. Based in Stoughton, Massachusetts, this specialty pharmaceutical company..

Immunome, Inc. (IMNM) Stock Analysis: Unveiling a 37.61% Upside Potential in Promising Cancer Therapies

Investors with an eye on the biotechnology sector have plenty to consider with Immunome, Inc. (NASDAQ: IMNM). This clinical-stage biotech company is making significant strides in the development of targeted..

Anavex Life Sciences Corp. (AVXL) Stock Analysis: Exploring a Potential 348% Upside in the Biotech Sector

For investors seeking opportunities in the dynamic biotech industry, Anavex Life Sciences Corp. (NASDAQ: AVXL) presents an intriguing prospect. With a market capitalization of $438.7 million, Anavex is a biopharmaceutical..

RxSight, Inc. (RXST) Stock Analysis: A 17.85% Potential Upside in the Healthcare Sector

RxSight, Inc. (RXST), a pioneering firm in the medical devices industry, is captivating investor attention with its innovative solutions in cataract surgery. Headquartered in Aliso Viejo, California, RxSight’s prime offering..

Pharvaris N.V. (PHVS) Stock Analysis: A Biotechnology Gem with 69% Upside Potential

Pharvaris N.V. (PHVS), a promising player in the biotechnology sector, has been capturing the attention of investors with its innovative approach to tackling rare diseases. Based in Zug, Switzerland, Pharvaris..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds